Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Teva Canada Announces the Launch of ACT Methylphenidate ER® Tablets, a Generic Version of Concerta® for the Treatment of ADHD

Teva Canada Limited
Posted on: 22 Mar 18
Teva Canada Announces the Launch of <C>ACT Methylphenidate ER® Tablets, a Generic Version of <C>Concerta® for the Treatment of ADHD

Canada NewsWire

TORONTO, March 22, 2018

- Currently available in Canada -

TORONTO, March 22, 2018 /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced that Health Canada has approved its application for CACT Methylphenidate ER® tablets, the generic version of CConcerta® (methylphenidate hydrochloride). This once-daily extended release medication is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in: Children (6 – 12 years of age); Adolescents (13 – 18 years of age); and Adults (>18 years of age).

Methylphenidate extended release tablets (brand: CConcerta®) had annual sales of approximately $175 million in Canada, based on IQVIA sales data as of January 2018.  CACT Methylphenidate ER® is available immediately to pharmacies across Canada.

"We've heard from healthcare providers, ADHD patients and their parents about the need for an affordable alternative to CConcerta® that works in the same way and at the same time," said David Boughner, Senior Director Commercial Management for Teva Canada Limited. "We're pleased to offer patients CACT Methylphenidate ER® as a bioequivalent modified release product that allows for a biphasic drug release profile after oral administration.  In addition, the pharmacokinetic parameters mimic the concentration-time release profile of CConcerta®."

Attention Deficit Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental disorder characterized by inattention, disorganization and/or hyperactivity or impulsivity. ADHD is the most common neurodevelopmental disorder in children, affecting about one in 20 children and is more common in boys than girls. ADHD persists into adulthood for at least 60% of children with the disorder. About 4.5% of adults have ADHD, but most have not been properly diagnosed or treated.  ADHD is highly treatable and people with ADHD can function well if they receive effective treatments and interventions.[i]

Helping People Live Better Days

At Teva, we help to improve the health of 200 million people every day by providing innovative treatments and access to the world's largest medicine cabinet of generic and specialty medicines. This gives us a unique perspective on health. Understanding the many ways health impacts people's lives inspires us to discover new possibilities to bring medicines and more, enabling patients and caregivers to live better days.

About Teva Canada Limited

Teva Canada Limited, headquartered in Toronto, has provided affordable healthcare solutions for 50 years, with sales of more than $1 billion[ii] in 2017 and over 249,000[iii] prescriptions filled with our products every day. Originally Novopharm Limited, Teva Canada Limited specializes in the development, production and marketing of high-quality generic prescription pharmaceuticals and through our branded division, Teva Canada Innovation, focuses on a diverse line of innovative products in a variety of therapeutic areas. Teva Canada employs more than 1,000 individuals, markets more than 400[iv] products in 1,700 SKUs in Canada and is a subsidiary of Teva Pharmaceutical Industries Ltd., the world's largest generic drug maker. For more information, visit: or

About Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2017 were $22.4 billion. For more information, visit

i Portico – Canada's Mental Health and Addiction Network. Attention-deficit/hyperactivity disorder: Overview – Accessed March 2018 – Accessed March 2018
ii Source: IQVIA CDH & Compuscript MAT January 2018
iii Source: IQVIA CDH & Compuscript MAT January 2018
iv Source: IQVIA CDH & Compuscript MAT January 2018

SOURCE Teva Canada Limited

PR Newswire

Last updated on: 22/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.